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Abstract
Dual blockade of the renin-angiotensin system (RAS) with a combination of angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers for the treatment of hypertension and
proteinuria has been tested in several randomized trials among patients with chronic kidney disease
(CKD). Although combination therapy reduces proteinuria and blood pressure, adequately powered
studies evaluating time to end-stage renal disease, death, or cardiovascular outcomes in patients with
CKD have not been done. Dual blockade of RAS can cause hyperkalemia, renal failure, and
orthostatic hypotension and potentially worsen outcomes; therefore, the risk-benefit ratio in patients
with CKD remains unclear. A recent randomized trial in patients with cardiovascular disease or high-
risk diabetes raises concerns about the safety of this combination therapy.
Introduction and context
Long-term follow-up of subjects with chronic kidney
disease (CKD) suggests that control of hypertension
slows the progression of CKD [1]. In patients with CKD,
angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) lower blood
pressure (BP) and also slow the progression of CKD
[2,3]. It appears that progression of CKD in these patients
may be due to effects beyond simply the lowering of BP
[4]. ARBs, when added to ACE inhibitors, can effectively
mitigate the increase in renin, angiotensin I, and
angiotensin II concentrations that may occur with long-
term ACE inhibition, referred to as ‘ACE escape’ [5].
Several small randomized trials evaluating the efficacy of
dual blockade for the treatment of hypertension and/or
proteinuria had found mixed results with generally low
incidences of reported adverse events.
Recent advances
Efficacy of dual renin-angiotensin system blockade
Overall, in subjects with diabetic nephropathy, a meta-
analysis found a favorable effect of dual renin-
angiotensin system (RAS) blockade on BP. Systolic BP
decreased by 4.2 mm Hg (95% confidence interval [CI]
1.1 to 7.2), and diastolic BP decreased by 2.8 mm Hg
(95% CI 1.2 to 4.6). In subjects with nondiabetic
proteinuric CKD, the pooled mean systolic BP decreased
by 4.9 mm Hg (95% CI 2.7 to 7.2) and the diastolic BP
decreased by 2.0 mm Hg (95% CI 1.2 to 2.9) when an
ARB was added to an ACE inhibitor [6]. Pooled estimates
of 24-hour urinary protein excretion demonstrate an
additional reduction of 440 mg/day (95% CI 289 to
591) from dual RAS blockade compared with ACE
inhibitor monotherapy [6]. In subjects with diabetes
mellitus (DM), this additional reduction was estimated
at 210 mg/day (95% CI 84 to 336), whereas in subjects
with nondiabetic proteinuric kidney disease, an addi-
tional 582 mg/day (95% CI 371 to 793) reduction was
observed [6]. The greater reduction in proteinuria among
patients with nondiabetic CKD is unknown but is likely
not due to a greater reduction in BP in these patients.
A more recent meta-analysis confirmed the favorable
effect of dual RAS on reduction in proteinuria over the
course of 12 months when compared with monotherapy
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of the level of baseline proteinuria [7].
In general, dual blockade leads to a reduction in
proteinuria but significant heterogeneity is seen among
trials [7]. For example, Agarwal [8] did not observe a
reduction in proteinuria in older people with more
severe kidney disease whereas Mogensen et al.[ 9 ]
observed a reduction in albuminuria when studying
diabetics with microalbuminuria. Accordingly, it is quite
possible that the reduction in proteinuria seen with
combination therapy may be a function of the severity of
kidney disease. In this context, albuminuria and glo-
merular filtration rate (GFR) are two separate measures
of severity of kidney disease. Characterizing the severity
of CKD on both of these measures of renal function
Perhaps the most promising trial supporting the role of
combination therapy was that reported by Nakao et al.
[10], who conducted a 3-year randomized trial called
COOPERATE (combination treatment of angiotensin II
receptor blocker and angiotensin-converting enzyme
inhibitor in nondiabetic renal disease). The trial ran-
domly assigned 263 Japanese subjects to receive losartan
100 mg, trandolapril 3 mg, or both for 3 years. This large,
relatively long trial found similar BP effects in study
cohorts treated with combination therapy versus mono-
therapy, but spectacular effects on rates of progression of
CKD were reported. The primary endpoint of doubling
of serum creatinine or end-stage renal disease was seen
in 10 of 85 patients (11%) on combination treatment
compared with 20 of 85 on trandolapril alone (23%)
(hazard ratio [HR] 0.38, 95% CI 0.18 to 0.63, P = 0.018)
and 20 of 86 on losartan alone (23%) (HR 0.40, 95% CI
0.17 to 0.69, P = 0.016). However, serious concerns
regarding the authenticity of this trial have been raised,
prompting the observation by the authors that originally
published BP data were erroneous due to data manage-
ment and other errors [11,12].
Safety of dual renin-angiotensin system blockade
Reporting of adverse events has been variable between
dual RAS blockage studies, with a recent meta-analysis
finding that only 33% of trials included reported
methods of assessing adverse events. Of these, the most
frequently reported reasons for discontinuing medica-
tions were dizziness, hyperkalemia, cough, allergies, and
hypertensive episodes [7]. Generally, smaller trials of
shorter duration have reported minimal adverse events.
Most trials assessing BP effect in subjects with CKD have
followed participants for 12 weeks or less, although one
trial of dubious quality followed subjects for 3 years as
discussed above [10]. In a meta-analysis by Mackinnon
et al. [6], the pooled decrease of estimated GFR (eGFR)
with combination therapy was −1.4 mL/minute (95%
CI −2.6 to 0.2). Pooled potassium data reveal a small
but statistically significant rise in serum potassium of
0.11 mmol/L (95% CI 0.05 to 0.17) [6].
The enthusiasm for dual RAS blockade has been
tempered by a large randomized double-blinded trial
that demonstrated a significant rate of serious adverse
events [13,14]. The Ongoing Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial
(ONTARGET) evaluated the combination of the ACE
inhibitor ramipril with the ARB telmisartan in 25,620
subjects (at least 55 years old) with established
atherosclerotic vascular disease or with diabetes with
end organ damage. Mean serum creatinine of the study
cohort was 93 µmol/L, and microalbuminuria was
present in 13% of subjects. Exclusion criteria included
serum creatinine of greater than 265 mmol/L and
uncontrolled hypertension (>160/100 mm Hg) on
treatment [15]. Subjects were randomly assigned to
receive telmisartan 80 mg/day, ramipril 10 mg/day, or
both. Participants were followed for a median of
56 months. At baseline, the mean BP was 141.8/
82.1 mm Hg in each treatment group. BP was reduced
at 6 weeks by 6.4/4.3 mm Hg in the ramipril group,
by 7.4/5.0 mm Hg in the telmisartan group, and by 9.8/
6.3 mm Hg in the combination therapy group. Progres-
sion of baseline microalbuminuria to macroalbumi-
nuria was significantly attenuated in the combination
group versus the ramipril group (HR 0.76, 95% CI
0.60 to 0.96, P = 0.019), with no differences between
ramipril and telmisartan [13]. Most of the small
numbers of events in this large trial were due to acute
renal failure, not end-stage renal disease. Notably, this
trial also excluded patients with more advanced CKD.
In contrast, the incidence of the primary renal composite
outcome (any dialysis, renal transplantation, doubling
of serum creatinine, or death) increased with combina-
tion therapy (14.5% of subjects taking combination
therapy; HR 1.09, 95% CI 1.01 to 1.18, P = 0.037).
Secondary renal outcomes included changes in eGFR and
progression of proteinuria [13]. Over the initial 2 years of
the trial, eGFR was significantly worse in both the
telmisartan and combination groups when compared
with ramipril alone (P < 0.0001). Renal abnormalities
were reported in significantly higher numbers in the
combination therapy group than in the ramipril cohort
(ramipril 10.2%, telmisartan 10.6%, and combination
therapy 13.5%, P < 0.001) and those renal abnormal-
ities were severe enough to necessitate permanently
stopping medication (0.7%, 0.8%, and 1.1%,
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could influence hard outcomes, and this should be tested
in future meta-analyses and clinical trials.respectively, P < 0.005). Hyperkalemia (serum potas-
sium >5.5 mmol/L) was worse in the combination
therapy group (P < 0.001) versus the ramipril group;
no significant differences were observed between the
ramipril and telmisartan groups [14]. The incidence of
acute dialysis was significantly greater in the combina-
tion group than in the ramipril group (HR 2.19, 95% CI
1.13 to 4.22, P = 0.02) and was similar in the ramipril
and telmisartan groups. There were no differences
between groups with respect to incidence of chronic
dialysis [13].
Implications for clinical practice
Although several trials have affirmed efficacy for BP
reduction, recent unfavorable safety data cast doubt on
the suitability of chronic dual RAS blockade in patients
with vascular disease and low levels of proteinuria.
Although the ONTARGET study did not address subjects
with advanced CKD and/or proteinuria, it seems
plausible that the safety profile of combination therapy
would be relevant to this patient population. This trial
suggests that dual blockade should be avoided in
patients with cardiovascular disease and those with
high-risk diabetes. However, since patients with more
advanced CKD or those with severe proteinuria were not
studied, the results of this trial do not apply to these
patients. Nonetheless, they raise the concern that
surrogate endpoints are not sufficient when judging the
safety and efficacy of dual blockade. Ongoing trials may
better illuminate the safety and efficacy of combination
therapy on hard endpoints among patients with CKD
[16,17].
Patients who are currently stable on combination
therapy present a management dilemma. Certainly, an
agent should be discontinued if sudden deterioration of
kidney function, hyperkalemia, hypotension, or hypo-
tensive symptoms such as syncope are noted.
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